GlassScriptPhysician profile
Sushil George
NPI 1740347681
$5,977.37
in general payments reported to CMS, 2019-2025
33 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $885 · 2021: $962 · 2022: $541 · 2023: $919 · 2024: $779 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.37 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,460.58 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,417.20 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $755.58 | 2019-2025 | Ofev, Stiolto Respimat |
| Mylan Specialty L.P. | $270.35 | 2020-2024 | Yupelri |
| Amgen INC. | $233.00 | 2023-2025 | Tezspire |
| Genzyme Corporation | $192.77 | 2020-2024 | |
| Genentech USA, INC. | $181.94 | 2019-2021 | |
| Viatris Specialty LLC | $148.81 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $140.17 | 2019-2023 | Uptravi |
| Intuitive Surgical, INC. | $139.84 | 2019 | |
| Inspire Medical Systems, INC. | $135.29 | 2023-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $101.69 | 2019-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $85.70 | 2021-2022 | |
| Pfizer INC. | $80.29 | 2019-2021 | |
| Insmed, INC. | $72.58 | 2020-2025 | Arikayce, Brinsupri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $56.70 | 2020 | |
| Electromed, INC. | $55.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $54.00 | 2020-2021 | |
| Lilly USA, LLC | $53.87 | 2025 | Zepbound |
| Harmony Biosciences LLC | $44.11 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $39.78 | 2021 | |
| Optinose US, INC. | $36.70 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.62 | 2019-2020 | |
| Philips North America LLC | $33.54 | 2020-2023 | |
| Pulmonx Corporation | $21.66 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Inogen, INC. | $19.88 | 2020 | |
| Kaleo, INC. | $19.12 | 2021 | |
| Advanced Respiratory, INC | $18.07 | 2021 | |
| Incyte Corporation | $17.49 | 2022 | |
| Gilead Sciences, INC. | $17.32 | 2021 | |
| Baxter Healthcare | $14.40 | 2023 | Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $12.89 | 2021 | |
| Mallinckrodt Enterprises LLC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushil George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.